Fig. 1From: Effect of age on pharmacokinetics, efficacy, and safety of galcanezumab treatment in adult patients with migraine: results from six phase 2 and phase 3 randomized clinical trialsEffect of age (18–65 years) on galcanezumab CL/F and V/FBack to article page